Euretina Innovation Spotlight (EIS) 2026 Presentation
Logotype for Oculis Holding AG

Oculis (OCS) Euretina Innovation Spotlight (EIS) 2026 Presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Oculis Holding AG

Euretina Innovation Spotlight (EIS) 2026 Presentation summary

1 Nov, 2026

Pipeline and planned catalysts

  • Privosegtor is a neuroprotective candidate for optic neuritis, NAION and acute MS relapses; it received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.

  • Planned milestones: PIONEER-2 and PIONEER-3 trial initiations in Q4 2026; new IND submission for MS relapses in Q4 2026; PIONEER-1 enrollment completion in 2027.

  • Licaminlimab is in a genotype-based development program for TNFR1-mediated dry eye disease; PREDICT-1 topline results anticipated around year-end 2026.

ACUITY Phase 2 trial

  • Randomized, double-masked, placebo-controlled, multicenter, 6-month study; 36 patients randomized, with mITT population of 33, for unilateral demyelinating optic neuritis with symptom onset within 12 days.

  • Participants received once-daily IV privosegtor for 5 days at 2 or 3 mg/kg plus steroid, or placebo plus steroid; safety was the primary endpoint, with visual function, retinal anatomy and neurofilament light chain as secondary measures.

  • No adverse events led to drug withdrawal or study discontinuation, and no drug-related serious adverse events were reported; two unrelated SAEs were recorded, one in each treatment group.

ACUITY efficacy findings

  • The 3 mg/kg/day arm showed clinically meaningful, sustained low-contrast visual acuity improvement; reported changes were +18 ETDRS letters (p=0.004) and +15 letters (p=0.012).

  • GCIPL thickness results showed 43% greater preservation with privosegtor than placebo at Months 3 and 6; nominal p-values were 0.049 and 0.052, respectively.

  • Plasma neurofilament light chain results showed a 47% reduction; the reported nominal p-value was 0.046.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Oculis